{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:15:36Z","timestamp":1767888936264,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T00:00:00Z","timestamp":1386979200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,12,14]],"date-time":"2013-12-14T00:00:00Z","timestamp":1386979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00508-013-0475-3","type":"journal-article","created":{"date-parts":[[2013,12,13]],"date-time":"2013-12-13T12:42:16Z","timestamp":1386938536000},"page":"133-137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study","Wirkung einer immunmodulatorischen Therapie beim ersten kroatischen Kind mit der Diagnose einer Pompe\u2019schen Krankheit: eine Verlaufsstudie \u00fcber 3 Jahre"],"prefix":"10.1007","volume":"126","author":[{"given":"Josko","family":"Markic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branka","family":"Polic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luka","family":"Stricevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitomir","family":"Metlicic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radenka","family":"Kuzmanic-Samija","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Kovacevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana Erceg","family":"Ivkosic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julije","family":"Mestrovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,14]]},"reference":[{"key":"475_CR1","unstructured":"Hirschhorn R, Reuser A. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The Metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p.\u00a03389\u2013420."},{"key":"475_CR2","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"der Ploeg AT van","year":"2008","unstructured":"van der Ploeg AT, Reuser AJ. Pompe\u2019s disease. Lancet. 2008;372:1342\u201353.","journal-title":"Lancet"},{"key":"475_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","volume":"148","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J\u00a0Pediatr. 2006;148:671\u20136.","journal-title":"J Pediatr"},{"key":"475_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","volume":"7","author":"MG Ausems","year":"1999","unstructured":"Ausems MG, Verbiest J, Hermans MP, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet. 1999;7:713\u20136.","journal-title":"Eur J Hum Genet"},{"key":"475_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K","volume":"79","author":"F Martiniuk","year":"1998","unstructured":"Martiniuk F, Chen A, Mack A, et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet. 1998;79:69\u201372.","journal-title":"Am J Med Genet"},{"issue":"2","key":"475_CR6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jpeds.2013.01.031","volume":"163","author":"CR Scott","year":"2013","unstructured":"Scott CR, Elliott S, Buroker N, et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr. 2013; 163(2):498\u2013503.","journal-title":"J Pediatr"},{"key":"475_CR7","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","volume":"11","author":"M Nicolino","year":"2009","unstructured":"Nicolino M, Byrne B, Wraith JE, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med. 2009;11:210\u20139.","journal-title":"Genet Med"},{"key":"475_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68:99\u2013109.","journal-title":"Neurology"},{"key":"475_CR9","first-page":"132","volume":"3","author":"A Amalfitano","year":"2001","unstructured":"Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial. Genet Med. 2001;3:132\u20138.","journal-title":"Genet Med"},{"key":"475_CR10","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N\u00a0Engl J Med. 2010;362:1396\u2013406.","journal-title":"N Engl J Med"},{"key":"475_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","volume":"149","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr. 2006;149:89\u201397.","journal-title":"J Pediatr"},{"key":"475_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99:26\u201333.","journal-title":"Mol Genet Metab"},{"key":"475_CR13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","volume":"13","author":"SG Banugaria","year":"2011","unstructured":"Banugaria SG, Prater SN, Ng YK, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011;13:729\u201336.","journal-title":"Genet Med"},{"key":"475_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ymgme.2009.07.001","volume":"98","author":"SE Lipinski","year":"2009","unstructured":"Lipinski SE, Lipinski MJ, Burnette A, Platts-Mills TA, Wilson\u00a0WG. Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa. Mol Genet Metab. 2009;98:319\u201321.","journal-title":"Mol Genet Metab"},{"key":"475_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/8904_2011_34","volume":"2","author":"J Markic","year":"2012","unstructured":"Markic J, Polic B, Kuzmanic-Samija R, et al. Immune modulation therapy in a CRIM-positive and IgG antibody-positive infant with Pompe disease treated with alglucosidase alfa: a case report. JIMD Rep. 2012;2:11\u20135.","journal-title":"JIMD Rep"},{"key":"475_CR16","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1056\/NEJMc0806809","volume":"360","author":"NJ Mendelsohn","year":"2009","unstructured":"Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in Pompe\u2019s disease. N Engl J Med. 2009;360:194\u20135.","journal-title":"N Engl J Med"},{"key":"475_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","volume":"106","author":"TT Patel","year":"2012","unstructured":"Patel TT, Banugaria SG, Case LE, Wenninger S, Schoser B, Kishnani PS. The impact of antibodies in late-onset Pompe disease: a case series and literature review. Mol Genet Metab. 2012;106:301\u20139.","journal-title":"Mol Genet Metab"},{"key":"475_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","volume":"101","author":"JM de Vries","year":"2010","unstructured":"de Vries JM, van der Beek NA, Kroos MA, et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab. 2010;101:338\u201345.","journal-title":"Mol Genet Metab"},{"key":"475_CR19","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","volume":"260","author":"A Toscano","year":"2013","unstructured":"Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J\u00a0Neurol. 2013;260:951\u20139.","journal-title":"J Neurol"},{"key":"475_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1365-2249.2008.03602.x","volume":"152","author":"A Joseph","year":"2008","unstructured":"Joseph A, Munroe K, Housman M, Garman R, Richards S. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin Exp Immunol. 2008;152:138\u201346.","journal-title":"Clin Exp Immunol"},{"key":"475_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ymgme.2012.01.019","volume":"105","author":"S Banugaria","year":"2012","unstructured":"Banugaria S, Patel T, Prater S, et al. The use of non-depleting anti-CD4 monoclonal antibody for immune tolerance induction in Pompe disease. Mol Genet Metab. 2012;105:290.","journal-title":"Mol Genet Metab"},{"key":"475_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ymgme.2012.11.033","volume":"108","author":"S Banugaria","year":"2013","unstructured":"Banugaria S, Prater S, Patel T, et al. Approach to management of cross-reactive immunologic material (CRIM)-negative infantile pompe patients treated with ERT: role of immune modulation in changing the natural history. Mol Genet Metab. 2013;108:23.","journal-title":"Mol Genet Metab"},{"key":"475_CR23","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1542\/peds.2003-0988-L","volume":"114","author":"TE Hunley","year":"2004","unstructured":"Hunley TE, Corzo D, Dudek M, et al. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics. 2004;114:532\u20135.","journal-title":"Pediatrics"},{"key":"475_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ymgme.2012.01.019","volume":"105","author":"SG Banugaria","year":"2012","unstructured":"Banugaria SG, Patel TT, Mackey J, et al. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. Mol Genet Metab. 2012;105:677\u201380.","journal-title":"Mol Genet Metab"},{"key":"475_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/gim.2012.110","volume":"15","author":"SG Banugaria","year":"2013","unstructured":"Banugaria SG, Prater SN, McGann JK, et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med. 2013;15:123\u201331.","journal-title":"Genet Med"},{"key":"475_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ajmg.c.31321","volume":"160","author":"LE Case","year":"2012","unstructured":"Case LE, Beckemeyer AA, Kishnani PS. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations. Am J Med Genet C Semin Med Genet. 2012;160:69\u201379.","journal-title":"Am J Med Genet C Semin Med Genet"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-013-0475-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-013-0475-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-013-0475-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-013-0475-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T13:13:30Z","timestamp":1589894010000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-013-0475-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,14]]},"references-count":26,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["475"],"URL":"https:\/\/doi.org\/10.1007\/s00508-013-0475-3","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,14]]},"assertion":[{"value":"22 June 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}